[go: up one dir, main page]

US20160051511A1 - Pharmaceutical Composition Containing Glimepiride and Metformin Hydrochloride - Google Patents

Pharmaceutical Composition Containing Glimepiride and Metformin Hydrochloride Download PDF

Info

Publication number
US20160051511A1
US20160051511A1 US14/727,396 US201514727396A US2016051511A1 US 20160051511 A1 US20160051511 A1 US 20160051511A1 US 201514727396 A US201514727396 A US 201514727396A US 2016051511 A1 US2016051511 A1 US 2016051511A1
Authority
US
United States
Prior art keywords
glimepiride
metformin hydrochloride
pharmaceutical composition
metformin
solid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/727,396
Inventor
José Manuel Francisco Lara Ochoa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silanes SA de CV
Original Assignee
Silanes SA de CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27607097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20160051511(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silanes SA de CV filed Critical Silanes SA de CV
Priority to US14/727,396 priority Critical patent/US20160051511A1/en
Assigned to SILANES S.A. DE C.V. reassignment SILANES S.A. DE C.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LARA OCHOA, JOSE MANUEL FRANCISCO
Publication of US20160051511A1 publication Critical patent/US20160051511A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • This invention consists of providing a therapeutic combination consisting of the sulfonylurea glimepiride and the biguanide metformin, both oral hypoglycemics, which, when combined, produce not only an additive effect but also a synergistic effect and therefore greater effectiveness in controlling blood glucose levels in patients with type 2 diabetes.
  • sulfonylureas act on the receptor in ⁇ pancreatic cells known as SUR, which, when it is activated, closes an ATP dependent potassium channel, which in turn causes a reduction in potassium intake and in consequence depolarization of the membrane. This in turn causes an increase in the flow of calcium toward the cell's interior, activating the cytoskeleton, which causes translocation of secretory granules, thereby releasing insulin by exocytosis.
  • Metformin acts effectively not only to control hypoglycemia, but also in its prevention.
  • Metformin has a different mechanism of action from sulfonylureas, increasing insulin sensitivity in hepatic and peripheral tissue (mainly muscular tissues). Metformin inhibits gluconeogenesis and hepatic glycogenolysis. At the cellular level, heightened insulin sensitivity is explained by the increased activity it induces in the tyrosin kinase post-receptor and the resulting increase in the number and activity of GLUT4 transporters.
  • WO 00/40233 describes a pharmaceutical composition of glimepiride and metformin.
  • this composition is designed to deliver an initial concentration of glimepiride, and later a delayed delivery of metformin.
  • a delayed delivery of metformin By this way of delivering both components it is not possible to maintain an appropriate bioavailability of the combined use of glimepiride and metformin to achieve a synergistic effect.
  • the ratio between metformin/glimepiride must be maintained in the range between about 500/1 to about 500/2 and using the appropriate dosage of metformin/glimepiride of 500/1, 500/2, 1000/2, 1000/4 (mg/mg), preferably 1000/2 mg/mg using a single dosage in a single tablet containing both drugs with 250 ml of water.
  • the half life of glimepiride was 3.73+/ ⁇ 1.28 hours, and of metformin was 2.62+/ ⁇ 0.33 hours.
  • HbA 1c glycosylated hemoglobin
  • FBG fasting blood glucose
  • PPBG post-prandial blood glucose
  • the purpose of this invention is to provide a pharmaceutical composition consisting of glimepiride and metformin as its hydrochloride salt, or any other salt, and oral hypoglycemic therapy combining glimepiride and metformin in a single fixed ratio that is more effective and just as safe as monotherapy with the same compounds in patients with uncontrolled type 2 diabetes mellitus.
  • Body mass index 27 kg/m 2 ;
  • glimepiride or metformin such as acetozolamide, nicotinic acid, para-aminosalicylic acid, non-steroidal anti-inflammatory analgesics, histamine antagonists 2, barbiturates, cyclophosamide, clonidine, cloranphenicol, cumarinics, disopyramide, epinephrine, estatines, fenfluramine, phenotiacine, fibrates, fluoxetine, guanitidine, steroid hormones, iphosamide, monoaminoxidase inhibitors, laxatives, miconazole, quinolones, reserpine, rifamicine, sulfamides, and tetracycline.
  • medications that present pharmacological interaction with glimepiride or metformin such as acetozolamide, nicotinic acid, para-aminosalicylic acid, non-steroidal anti-inflammatory analgesics, histamine antagonist
  • Levels of glycemia between meals >139 mg/dL are defined as type 2 diabetes mellitus.
  • Severe hypoglycemia Glycemia between meals >260 mg/dL.
  • Severe hypoglycemia Glycemia ⁇ 60 mg/dL.
  • Non-adherence Medication absorption ⁇ 80%.
  • Glimepiride (2 mg tablets) Glycemia 140-180 mg/dl 1 mg 1 ⁇ 2 tablet Glycemia 181-220 mg/dl 2 mg 1 tablet Glycemia 221-260 mg/dl 4 mg 2 tablets b) Metformin (1000 mg tablets) Glycemia 140-180 mg/dl 500 mg 1 ⁇ 2 tablet Glycemia 181-220 mg/dl 1000 mg 1 tablet Glycemia 221-260 mg/dl 2000 mg 2 tablets c) Glimepiride/Metformin ( 2/1000 mg tablets) 140-180 mg/dl 1/500 mg 1 ⁇ 2 tablet
  • results obtained show that combined metformin and glimepiride therapy was more effective in controlling glucosylated hemoglobin levels, post-prandial blood glucose levels and blood glucose levels between meals than single-drug treatment with glimepiride or metformin alone.
  • the results obtained are shown below:
  • a pharmaceutical composition consisting of 500 mg of metformin hydrochloride and 1 mg of glimepiride, adding the following excipients:
  • This pharmaceutical composition was used for the aforementioned clinical tests.
  • a pharmaceutical composition consisting of 500 mg of metformin hydrochloride and 2 mg of glimepiride, adding the following excipients:
  • This pharmaceutical composition was used for the aforementioned clinical tests.
  • a pharmaceutical composition consisting of 1000 mg of metformin hydrochloride and 2 mg of glimepiride, adding the following excipients:
  • This pharmaceutical composition was used for the aforementioned clinical tests.
  • a pharmaceutical composition consisting of 1000 mg of metformin hydrochloride and 4 mg of glimepiride, adding the following excipients:
  • This pharmaceutical composition was used for the aforementioned clinical tests.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Pharmaceutical compositions of the active substances glimepiride with metformin or its salts such as hydrochloride, succinate, fumarate, etc. are useful to control blood glucose in patients with type 2 diabetes. To prove the effectiveness of the combination, clinical studies were conducted that demonstrated the existence of not only an additive effect, but also a synergistic effect of the two drugs compared with monotherapy using only one of the drugs used in combination. In consequence, the combination may be used as an effective and safe therapy to control blood glucose in patients with type 2 diabetes, using different proportions of the active substances in combinations suitable for the needs of different patients.

Description

    FIELD OF THE INVENTION
  • This invention consists of providing a therapeutic combination consisting of the sulfonylurea glimepiride and the biguanide metformin, both oral hypoglycemics, which, when combined, produce not only an additive effect but also a synergistic effect and therefore greater effectiveness in controlling blood glucose levels in patients with type 2 diabetes.
    • BACKGROUND
  • The use of sulfonylureas in treating type 2 diabetes is fully established as an effective means of controlling hypoglycemia. At the molecular level, sulfonylureas act on the receptor in β pancreatic cells known as SUR, which, when it is activated, closes an ATP dependent potassium channel, which in turn causes a reduction in potassium intake and in consequence depolarization of the membrane. This in turn causes an increase in the flow of calcium toward the cell's interior, activating the cytoskeleton, which causes translocation of secretory granules, thereby releasing insulin by exocytosis.
  • Another treatment whose use has spread recently is with the biguanide metformin, which acts effectively not only to control hypoglycemia, but also in its prevention. Metformin has a different mechanism of action from sulfonylureas, increasing insulin sensitivity in hepatic and peripheral tissue (mainly muscular tissues). Metformin inhibits gluconeogenesis and hepatic glycogenolysis. At the cellular level, heightened insulin sensitivity is explained by the increased activity it induces in the tyrosin kinase post-receptor and the resulting increase in the number and activity of GLUT4 transporters.
  • However, around 75% of type 2 diabetes patients treated with sulfonylureas do not succeed in bringing their glucose level to the desired values, and need to complement their treatment with a second oral agent. Also, most patients with single drug treatment using sulfonylureas after a certain number of years require an additional drug that contributes to their control therapy in order to achieve a suitable level of glycemic control. This loss of effectiveness is attributed to various causes, which are not yet well established, such as the supposition that gradual deterioration of the pancreas renders it unable to maintain an exacerbated insulin excretion rate for a long period of time due to constant, long-term stimulation caused by sulfonylurea therapy. However, contrary to this explanation, metformin therapy, which does not act by over stimulating β cells, also presents lack of response after prolonged use, which would be contradictory to the explanation given for the lack of response of sulfonylureas.
  • On the other hand it has been found that combining sulfonylurea and metformin therapy is more effective than monotherapy with either of the two medications. Thus, it has been fully proven that the hypoglycemic action of metformin is completely additional to that of sulfonylureas (de Fronzo, R. A. and Goodman, A. M. Yn, England J. Med. 333:541 (1995)).
  • It also has been reported that when monotherapy with sulfonylureas does not achieve the desired levels it should not be discontinued and replaced by metformin monotherapy, as this will not lower glucose levels in plasma below the values observed with sulfonylurea monotherapy (Rosenstock, J. et al., Diabetes Care 19:1994 (1996); (Gasber, A. J., et al., Amer. J. Med. 103:491 (1997)).
  • It is generally recognized that, because diabetes mellitus is a progressive disease, patients with good initial response to oral agents will eventually require a second medication to achieve the desired glycemic control. As we have mentioned, adding metformin to sulfonylurea therapy or vice-versa produces an additive response, not only to the reduction in glucose, but also to the reduction in lipids (Hermann, L. S., et al., Diabetes Care, 17:1100 (1994)).
  • There are several reports on the combined use of the sulfonylurea glibenclamide with the biguanide metformin. See, e.g., WO 97/17975; Vigneri et al., Diabetes and Metabolism, 17:232-234 (1991); Higginbotham et al., Med. J. Austr., 154-156 (1979); U.S. Pat. No. 6,303,146; and WO 01/32,158.
  • Furthermore, there are several references on the combined use of the sulfonylurea glipizide with metformin. See, e.g., Cefalu et al., Diabetes, 45 (Supl. 2):201A (1996); Croase et al., Circulation, 94 Supl 1508 (1996); and Cefalu et al., Diabetology, 39 (Supl. 1): A231 (1996).
  • It has been reported that there are no great differences in efficacy among various sulfonylureas (R. A. De Fronzo, Annals of Internal Medicine, 131:281-303 (1999)); S. Dagogo-Jack, et al., Archives Internal Medicine, 157:1802-1817 (1997); A. J. Scheen et al., Drugs 55:225-236 (1998); R. Bressler et al., Archives Internal Medicine, 157:836-848 (1997). Other reports indicate that glimepiride shows a potency two times higher than that of glibenclamide (R. Groomis et al., Endocrinology, 13:117-121 (2000)). Moreover, in contrast to glibenclamide, chronic treatment of type 2 diabetic patients with glimepiride will not impair the vasodilator function of KATP opening in vivo (E. J. Abbink et al., Diabetic Medicine, 19:136-143 (2002). Furthermore, a lower incidence of severe hypoglycemia was reported in type 2 diabetic patients treated with glimepiride versus glibenclamide (A. Holstein et al. Diabetologia, 157:A40 (2000). Finally, Kramer et al., Biochimica et Biphysica Acta 1191:276-290 (1999)), reported that glimepiride acts on a different receptor site on the β-cell than does glibenclamide, and that glimepiride interacts with the β-cell receptor for less time. Unlike glibenclamide, glimepiride seems to work in part by enhancing both the sensitivity and responsiveness of peripheral tissue to insulin (J. Sato et al. Excerpta Medica, 341-348 (1994), G. E. Sonnenberg et al., Annales Pharmaceuticals, 31:671-676 (1997)).
    • DESCRIPTION OF THE INVENTION
  • Combined glimepiride and metformin have been suggested previously in the literature (G. Charpentier et al. Diabetic Medicine 18:828-834 (2001)). However, very little data is provided on its advantages or appropriate dosages. The prescribing information for the drug Amaryl (which active ingredient is glimepiride) warns of its supposed risk of hypoglycemia due to concomitant use metformin (Physicians Desk Reference, 54 Edition, 2000, page 1349). Thus, the current state of the art does not suggest the development and use of a pharmaceutical composition combining glimepiride and metformin, which in the present invention has been found to offer unexpected advantages.
  • With the present invention we have performed clinical studies which indicate that a pharmaceutical composition comprising a combination of glimepiride and metformin in determined fixed ratios decreased the glycosylated haemoglobin (HbA1c) in a synergistic way compared to using glimepiride and metformin separately (Gonzalez-Ortiz et al., Rev. Inv. Clin. 56, in press, 2004). That is, the combined use of both drugs in certain ratios displays a synergistic effect on the efficacy greater than the additive efficacy of glimepiride and metformin used separately. This synergistic effect, beside being manifested in the control of glycosylated haemoglobin (HbA1c), also controls fasting blood glucose (FBG) and post-prandial blood glucose (PPBG).
  • WO 00/40233 describes a pharmaceutical composition of glimepiride and metformin. However, this composition is designed to deliver an initial concentration of glimepiride, and later a delayed delivery of metformin. By this way of delivering both components it is not possible to maintain an appropriate bioavailability of the combined use of glimepiride and metformin to achieve a synergistic effect.
  • In the clinical studies performed concerning the present invention, it has been found that in order to obtain a pharmaceutical synergy, the ratio between metformin/glimepiride must be maintained in the range between about 500/1 to about 500/2 and using the appropriate dosage of metformin/glimepiride of 500/1, 500/2, 1000/2, 1000/4 (mg/mg), preferably 1000/2 mg/mg using a single dosage in a single tablet containing both drugs with 250 ml of water. After 10 hr of fasting in 16 healthy volunteers, 8 men and 8 women, the plasma concentrations of glimepiride was Cmax=194.43+/−63.51 ng/ml and for metformin 2245.16+/−580.91 ng/ml in a time of 1.98+/1−0.59 his and 1.56+/−0.56 hrs, respectively. The half life of glimepiride was 3.73+/−1.28 hours, and of metformin was 2.62+/−0.33 hours. Using these conditions and the mentioned ratio of glimepiride and metformin a synergistic control was observed in the glycosylated hemoglobin (HbA1c), in the control of fasting blood glucose (FBG), and in the post-prandial blood glucose (PPBG).
  • The great inconvenience of the pharmaceutical composition described in the above mentioned patent WO 00/40233 A is that there is an initial and total delivery of glimepiride followed by a delayed delivery of metformin. Taking into account the short half life of glimepiride (around 3.73 hours), when the metformin starts delivering the glimepiride concentration in the blood will be falling such that there will be a variable proportion of both drugs in the blood as a function of time. After a longer period of time, the glimepiride will be cleared from the blood and only the delayed metformin will persist. The net effect is a sequential medication of glimepiride alone followed by a combined medication of glimepiride and metformin with variable concentrations in the blood, followed by the supply of metformin alone. With this type of bioavailability, it will be impossible to observe any synergistic effect of the combination of both drugs.
  • The purpose of this invention is to provide a pharmaceutical composition consisting of glimepiride and metformin as its hydrochloride salt, or any other salt, and oral hypoglycemic therapy combining glimepiride and metformin in a single fixed ratio that is more effective and just as safe as monotherapy with the same compounds in patients with uncontrolled type 2 diabetes mellitus.
  • To demonstrate the above, a random double blind clinical study was conducted with a universe of 30 patients with uncontrolled type 2 diabetes mellitus who receive monotherapy with sulfonylureas or biguanides per group.
  • Criteria for inclusion were as follows:
  • 1. Body mass index=27 kg/m2;
  • 2. Age 40 to 65;
  • 3. Capacity for deglutition; and
  • 4 Voluntary consent
  • Criteria for exclusion were as follows:
  • 1. Pregnancy;
  • 2. Insulin treatment; and
  • 3. Personal background of systemic diseases such as:
      • a) Cardiac insufficiency; and
      • b) Hepatic or chronic hepatopathic insufficiency.
  • 4 Background of significant chronic complications with type 2 diabetes mellitus:
      • a) Renal insufficiency;
      • b) Ischemic cardiopathy;
      • c) Cerebral vascular disease; and
      • d) Visceral neuropathy.
  • 5. Background of short-term terminal diseases, such as:
      • a) Cancer; and
      • b) HIV
  • 6. Therapy with medications that present pharmacological interaction with glimepiride or metformin, such as acetozolamide, nicotinic acid, para-aminosalicylic acid, non-steroidal anti-inflammatory analgesics, histamine antagonists 2, barbiturates, cyclophosamide, clonidine, cloranphenicol, cumarinics, disopyramide, epinephrine, estatines, fenfluramine, phenotiacine, fibrates, fluoxetine, guanitidine, steroid hormones, iphosamide, monoaminoxidase inhibitors, laxatives, miconazole, quinolones, reserpine, rifamicine, sulfamides, and tetracycline.
  • 7. Known intolerance or allergies to sulfonylureas or biguanides.
  • Criteria for exclusion from the therapy, but not from the statistical analysis:
  • 1. Presence of severe hypoglycemia at the maximum dosages used in the study;
  • 2. Presence of severe hypoglycemia at the minimum dosages used in the study;
  • 3. Presence of intolerable undesirable effects with any of the medications used in the study;
  • 4. Failure to follow the medical treatment indicated;
  • 5. Failure to attend scheduled visits;
  • 6. Intercurrent illnesses or accidents that warrant hospitalization;
  • 7. Administration during the study of medications with pharmacological interaction with metformin or glimepiride; and
  • 8. Voluntary withdrawal from the study.
  • The variables studied were as follows:
  • Dependent variables:
      • a) Glycemia between meals;
      • b) Glucosylated hemoglobin;
      • c) β-cell function;
      • d) Insulin resistance; and
      • e) Metabolic profile.
  • Independent variable:
      • a) Hypoglycemic therapy.
  • Intervening variables:
      • a) Age;
      • b) Sex;
      • c) Body mass index; and
      • d) Evolution of diabetes.
    DEFINITIONS
  • Levels of glycemia between meals >139 mg/dL are defined as type 2 diabetes mellitus.
  • Severe hypoglycemia: Glycemia between meals >260 mg/dL.
  • Severe hypoglycemia: Glycemia <60 mg/dL.
  • Non-adherence: Medication absorption <80%.
  • Absence: Missed appointment on >1 occasion.
  • Procedure
  • Identification, clinical history and selection of participants:
  • Clinical measurements and basal measurement of glycemia between meals, glucosylated hemoglobin, total cholesterol, cholesterol of high density lipoproteins, triglycerides, creatinine, uric acid, glutemic-oxaloacetic transaminase, glutemic-pyruvic transaminase, lactic dehydrogenase, alkaline and insulin phosphatase.
  • Random assignment of patients to each group and pharmacological intervention in accordance with concentration of basal glycemia:
  •
    a) Glimepiride (2 mg tablets)
    Glycemia 140-180 mg/dl 1 mg ½ tablet
    Glycemia 181-220 mg/dl 2 mg 1 tablet
    Glycemia 221-260 mg/dl 4 mg 2 tablets
    b) Metformin (1000 mg tablets)
    Glycemia 140-180 mg/dl 500 mg ½ tablet
    Glycemia 181-220 mg/dl 1000 mg 1 tablet
    Glycemia 221-260 mg/dl 2000 mg 2 tablets
    c) Glimepiride/Metformin ( 2/1000 mg
    tablets)
    140-180 mg/dl 1/500 mg ½ tablet
  • Clinical evaluation 30 and 60 days after beginning the study, measuring glycemia between meals and lactic dehydroginase.
  • Final clinical evaluations 90 days after the study begins, measuring glycemia between meals, glucosylated hemoglobin, total cholesterol, high density lipoprotein cholesterol, triglyceride, creatinine, uric acid, glutemic-oxaloacetic transaminase, glutemic-pyruvic transaminase, lactic dehydrogenase, alkaline and insulin phosphatase.
  • Undesirable effects were reported on a special record sheet, specifying each of the clinical manifestations considered probable, possible or directly related to the use of the drugs ingested.
  • The results obtained show that combined metformin and glimepiride therapy was more effective in controlling glucosylated hemoglobin levels, post-prandial blood glucose levels and blood glucose levels between meals than single-drug treatment with glimepiride or metformin alone. The results obtained are shown below:
  • Combination glimepiride metformin
    Glucosylated hemoglobin HbA1c −0.70 +0.25 +0.06
    Blood glucose between meals −1.77 +0.68 +0.75
    Post-prandial blood glucose −2.7 +0.99 +1.08
  • What is extraordinary about the values obtained is that monotherapy with either glimepiride or metformin has a similar effect in raising glucose levels, while treatment with the combination clearly shows a beneficial effect, which highlights its importance.
  • The previous combinations used in the clinical study can be illustrated by means of the following examples:
    • Example 1
  • A pharmaceutical composition is prepared consisting of 500 mg of metformin hydrochloride and 1 mg of glimepiride, adding the following excipients:
  •
    Microcrystalline Cellulose PH 101 39.20 mg
    Coloidal Silica Dioxide  1.80 mg
    Povidone K-90 18.00 mg
    Croscarmelose Sodium 12.00 mg
    Magnesium stereate  3.00 mg
    Clear Opadray YS-1-7006  5.00 mg
    Purified water 0.204 mg
  • This pharmaceutical composition was used for the aforementioned clinical tests.
    • Example 2
  • A pharmaceutical composition is prepared consisting of 500 mg of metformin hydrochloride and 2 mg of glimepiride, adding the following excipients:
  •
    Microcrystalline Cellulose PH 101 38.20 mg
    Coloidal Silica Dioxide  1.80 mg
    Povidone K-90 18.00 mg
    Croscarmelose Sodium 12.00 mg
    Magnesium stereate  3.00 mg
    Clear Opadray YS-1-7006  5.00 mg
    Purified water 0.204 mg
  • This pharmaceutical composition was used for the aforementioned clinical tests.
    • Example 3
  • A pharmaceutical composition is prepared consisting of 1000 mg of metformin hydrochloride and 2 mg of glimepiride, adding the following excipients:
  •
    Microcrystalline Cellulose PH 101 78.40 mg
    Coloidal Silica Dioxide 3.60 mg
    Povidone K-90 36.00 mg
    Croscarmelose Sodium 24.00 mg
    Magnesium stereate 6.00 mg
    Clear Opadray YS-1-7006 6.25 mg
    Purified water 0.345 ml
  • This pharmaceutical composition was used for the aforementioned clinical tests.
    • Example 4
  • A pharmaceutical composition is prepared consisting of 1000 mg of metformin hydrochloride and 4 mg of glimepiride, adding the following excipients:
  •
    Microcrystalline Cellulose PH 101 78.40 mg
    Coloidal Silica Dioxide 3.60 mg
    Povidone K-90 36.00 mg
    Croscarmelose Sodium 24.00 mg
    Magnesium stereate 6.00 mg
    Clear Opadray YS-1-7006 6.25 mg
    Purified water 0.345 ml
  • This pharmaceutical composition was used for the aforementioned clinical tests.

Claims (21)

1-11. (canceled)
12. A solid pharmaceutical composition, comprising a synergistic combination of glimepiride and metformin hydrochloride, wherein the weight ratio of glimepiride and metformin hydrochloride is about 1/250, wherein the combination of glimepiride and metformin hydrochloride reduces blood glucose levels in a patient with type 2 diabetes greater than either glimepiride or metformin hydrochloride alone, and wherein the composition further comprises 18 mg to 36 mg of povidone, 3 mg to 6 mg of magnesium stearate, and 1.8 mg to 3.6 mg of colloidal silicon dioxide.
13. The solid pharmaceutical composition according to claim 12, comprising 1,000 mg metformin hydrochloride and 4 mg glimepiride.
14. The solid pharmaceutical composition according to claim 12, comprising 500 mg metformin hydrochloride and 2 mg glimepiride.
15. A method of controlling blood glucose levels in a patient with type 2 diabetes, comprising administering the composition of claim 12 to said patient.
16. The method according to claim 15, comprising administering a composition wherein glimepiride and metformin hydrochloride are present in amounts of 2 mg glimepiride and 500 mg metformin hydrochloride or 4 mg glimepiride and 1,000 mg metformin hydrochloride.
17. The method according to claim 15, comprising administering a composition wherein glimepiride and metformin hydrochloride are present in amounts of 2 mg glimepiride and 500 mg metformin hydrochloride.
18. The method according to claim 15, comprising administering a composition wherein glimepiride and metformin hydrochloride are present in amounts of 4 mg glimepiride and 1,000 mg metformin hydrochloride.
19. The solid pharmaceutical composition according to claim 12, wherein the combination of glimepiride and metformin hydrochloride reduces blood glucose levels in a patient with type 2 diabetes greater than the additive effect of glimepiride and metformin hydrochloride alone.
20. The method according to claim 15, wherein the combination of glimepiride and metformin hydrochloride reduces blood glucose levels in a patient with type 2 diabetes greater than the additive effect of glimepiride and metformin hydrochloride alone.
21. The solid pharmaceutical composition according to claim 12, wherein the combination of glimepiride and metformin hydrochloride reduces glycosylated hemoglobin levels in a patient with type 2 diabetes greater than either glimepiride or metformin hydrochloride alone.
22. The method according to claim 15, wherein the combination of glimepiride and metformin hydrochloride reduces glycosylated hemoglobin levels in a patient with type 2 diabetes greater than either glimepiride or metformin hydrochloride alone.
23. The solid pharmaceutical composition according to claim 21, wherein the combination of glimepiride and metformin hydrochloride reduces glycosylated hemoglobin levels in a patient with type 2 diabetes greater than the additive effect of glimepiride and metformin hydrochloride alone.
24. The method according to claim 22, wherein the combination of glimepiride and metformin hydrochloride reduces glycosylated hemoglobin levels in a patient with type 2 diabetes greater than the additive effect of glimepiride and metformin hydrochloride alone.
25. The solid pharmaceutical composition according to claim 12, further comprising microcrystalline cellulose and croscarmellose sodium.
26. The solid pharmaceutical composition according to claim 25, further comprising opadry clear.
27. The solid pharmaceutical composition according to claim 12, further comprising 18 mg of povidone, 3 mg of magnesium stearate, and 1.8 mg of colloidal silicon dioxide.
28. The solid pharmaceutical composition according to claim 12, further comprising 36 mg of povidone, 6 mg of magnesium stearate, and 3.6 mg of colloidal silicon dioxide.
29. The solid pharmaceutical composition according to claim 13, further comprising 36 mg of povidone, 6 mg of magnesium stearate, and 3.6 mg of colloidal silicon dioxide.
30. The solid pharmaceutical composition according to claim 14, further comprising 18 mg of povidone, 3 mg of magnesium stearate, and 1.8 mg of colloidal silicon dioxide.
31. The method according to claim 18, wherein the composition further comprises 36 mg of povidone, 6 mg of magnesium stearate, and 3.6 mg of colloidal silicon dioxide.
US14/727,396 2002-01-25 2015-06-01 Pharmaceutical Composition Containing Glimepiride and Metformin Hydrochloride Abandoned US20160051511A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/727,396 US20160051511A1 (en) 2002-01-25 2015-06-01 Pharmaceutical Composition Containing Glimepiride and Metformin Hydrochloride

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/MX2002/000003 WO2003061643A1 (en) 2002-01-25 2002-01-25 Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes
US50240305A 2005-06-20 2005-06-20
US14/727,396 US20160051511A1 (en) 2002-01-25 2015-06-01 Pharmaceutical Composition Containing Glimepiride and Metformin Hydrochloride

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/502,403 Continuation US9045438B2 (en) 2002-01-25 2002-01-25 Pharmaceutical composition containing glimepiride and metformin hydrochloride
PCT/MX2002/000003 Continuation WO2003061643A1 (en) 2002-01-25 2002-01-25 Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes

Publications (1)

Publication Number Publication Date
US20160051511A1 true US20160051511A1 (en) 2016-02-25

Family

ID=27607097

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/502,403 Expired - Fee Related US9045438B2 (en) 2002-01-25 2002-01-25 Pharmaceutical composition containing glimepiride and metformin hydrochloride
US14/727,396 Abandoned US20160051511A1 (en) 2002-01-25 2015-06-01 Pharmaceutical Composition Containing Glimepiride and Metformin Hydrochloride

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/502,403 Expired - Fee Related US9045438B2 (en) 2002-01-25 2002-01-25 Pharmaceutical composition containing glimepiride and metformin hydrochloride

Country Status (11)

Country Link
US (2) US9045438B2 (en)
EP (1) EP1482919B1 (en)
AT (1) ATE361065T1 (en)
BR (1) BRPI0502691A (en)
CY (1) CY1106771T1 (en)
DE (1) DE60219963T2 (en)
DK (1) DK1482919T3 (en)
ES (1) ES2284829T3 (en)
MX (1) MXPA04007183A (en)
PT (1) PT1482919E (en)
WO (1) WO2003061643A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660939B2 (en) 2015-04-14 2020-05-26 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007183A (en) 2002-01-25 2006-03-06 Silanes Sa De Cv Lab Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes.
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
MXPA05009633A (en) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Stable pharmaceutical composition comprising immediate-release glimepiride and delayed-release metformin.
FR2896157B1 (en) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SECRETION STIMULATION AGENTS.
BR112012026005A2 (en) * 2010-04-13 2015-09-08 Nucitec Sa De Cv compositions and methods for treating type ii diabetes and related disorders
MX339374B (en) * 2011-04-29 2016-05-13 Inst De Investigación En Química Aplic S A De C V Metformin-based ionic co-crystals.
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
EP2712628B1 (en) * 2012-09-28 2016-08-10 Shanta Banerjee Composition for use as a medicine or dietetic food, in particular in the prevention and/or treatment of Diabetes and diabetes associated diseases
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
CA2927335C (en) 2014-10-27 2023-05-02 Aseko, Inc. Subcutaneous outpatient management
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072527A (en) 1959-07-01 1963-01-08 Horner Frank W Ltd Use of tolbutamide in the treatment of acne
JP3465247B2 (en) 1992-12-28 2003-11-10 アベンティス ファーマ株式会社 Prevention and treatment of arteriosclerosis
DE4432757A1 (en) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmaceutical preparation containing metformin and process for its preparation
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
IT1276130B1 (en) 1995-11-14 1997-10-27 Gentili Ist Spa GLIBENCLAMIDE-METFORMIN ASSOCIATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND THEIR USE IN THE TREATMENT OF TYPE DIABETES MELLITUS
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
DE69822505T2 (en) * 1997-12-08 2005-01-20 Bristol-Myers Squibb Co. NEW METFORMIN SALTS AND METHODS
EP0974356B1 (en) 1998-07-15 2003-09-24 Merck Sante Tablets comprising a combination of metformin and glibenclamide
DE19860698A1 (en) * 1998-12-30 2000-07-06 Hexal Ag New pharmaceutical composition
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
RU2003104808A (en) * 2000-08-07 2004-08-20 Ранбакси Сигниче Ллк (Us) LIQUID COMPOSITION OF METFORMINE
FR2825023B1 (en) 2001-05-23 2005-04-15 Flamel Tech Sa ANTIDIABETIC ORAL PHARMACEUTICAL FORM "ONE TAKEN PER DAY" INCLUDING BIGUANIDE AND AT LEAST ONE OTHER ACTIVE INGREDIENT
MXPA04007183A (en) 2002-01-25 2006-03-06 Silanes Sa De Cv Lab Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes.
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
AU2003276572A1 (en) 2002-11-15 2004-06-15 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
MXPA05009633A (en) 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Stable pharmaceutical composition comprising immediate-release glimepiride and delayed-release metformin.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660939B2 (en) 2015-04-14 2020-05-26 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications

Also Published As

Publication number Publication date
WO2003061643A1 (en) 2003-07-31
DE60219963T2 (en) 2008-02-07
EP1482919A1 (en) 2004-12-08
US20050239887A1 (en) 2005-10-27
CY1106771T1 (en) 2012-05-23
ES2284829T3 (en) 2007-11-16
DK1482919T3 (en) 2007-07-30
EP1482919B1 (en) 2007-05-02
BRPI0502691A (en) 2006-03-07
PT1482919E (en) 2007-07-25
MXPA04007183A (en) 2006-03-06
DE60219963D1 (en) 2007-06-14
ATE361065T1 (en) 2007-05-15
US9045438B2 (en) 2015-06-02

Similar Documents

Publication Publication Date Title
US20160051511A1 (en) Pharmaceutical Composition Containing Glimepiride and Metformin Hydrochloride
CA2622472C (en) Dipeptidyl peptidase inhibitors for treating diabetes
Scheen Clinical pharmacokinetics of metformin
ES2302702T3 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF METFORMIN AND GLIBENCLAMIDE.
EP1743655B1 (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
CA2663279C (en) Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
JP2004155791A (en) Novel NIDDM therapy
US8492426B1 (en) Use of carvedilol for treatment of diabetes mellitus
EA032085B1 (en) Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
JP2008509145A (en) Anti-diabetic oral insulin-biguanide combination
US5885980A (en) Composition and method for treating diabetes
US20050256131A1 (en) Pharmaceutical active substance combination and the use thereof
US20090221652A1 (en) Combinations of metformin and meglitinide
Brown et al. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy
Padgilwar et al. Recent Drug Advances in the Management of Diabetes Complications: An Overview
Seetho et al. The clinical management of diabetes mellitus
US20080015229A1 (en) Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
KR20190074746A (en) Pharmaceutical formulation for preventing or treating diabetes mellitus comprising cyclo-hispro
US20130030053A1 (en) Novel niddm regimen
WO2004002474A1 (en) Drug composition for prevention or inhibition of advance of diabetic complication
WO2002076462A1 (en) Drugs for improving insulin resistance
ZA200305225B (en) Spaced drug delivery system.
Gostling Do insulin secretagogues remain essential in managing type 2 diabetes?
WO1997002818A1 (en) Composition and method for treating diabetes
Gordon 4 The person with type 2 diabetes

Legal Events

Date Code Title Description
AS Assignment

Owner name: SILANES S.A. DE C.V., MEXICO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LARA OCHOA, JOSE MANUEL FRANCISCO;REEL/FRAME:036729/0943

Effective date: 20050603

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION